| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 51 |
| 1 | TACROLIMUS | 38 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 36 |
| 3 | TACROLIMUS OINTMENT 0.1% | 36 |
| 4 | DOXORUBICIN | 34 |
| 5 | GEMCITABINE HYDROCHLORIDE | 31 |
| 6 | PREDNISONE | 28 |
| 7 | MYCOPHENOLIC ACID | 27 |
| 8 | MYCOPHENILIC ACID | 25 |
| 9 | GEMCITABINE | 21 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DUVELISIB | 4 | 0.0047 |
| 1 | TREOSULFAN | 6 | 0.0022 |
| 2 | CIDOFOVIR ANHYDROUS | 3 | 0.0021 |
| 3 | SIROLIMUS | 17 | 0.0012 |
| 4 | MYCOPHENILIC ACID | 25 | 0.0012 |
| 5 | BASILIXIMAB | 13 | 0.0011 |
| 6 | BELATACEPT | 5 | 0.0011 |
| 7 | FRUQUINTINIB | 4 | 0.0010 |
| 8 | FOSNETUPITANT AND PALONOSETRON | 1 | 0.0008 |
| 9 | NETUPITANT AND PALONOSETRON | 1 | 0.0008 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antimetabolite Immunosuppressant [EPC] | 25 | 0.0012 |
| 1 | Endoglycosidase [EPC] | 2 | 0.0011 |
| 2 | Selective T Cell Costimulation Blocker [EPC] | 5 | 0.0011 |
| 3 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 3 | 0.0005 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 54 | 0.0003 |
| 5 | Radioligand Therapeutic Agent [EPC] | 4 | 0.0003 |
| 6 | CD52-directed Cytolytic Antibody [EPC] | 5 | 0.0003 |
| 7 | Androgen [EPC] | 7 | 0.0003 |
| 8 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 1 | 0.0002 |
| 9 | CD38-directed Cytolytic Antibody [EPC] | 1 | 0.0002 |